21^st Global Biomarkers and Clinical Research Summit

Dr. Búko has served as the Vice President of Human Metabolome Technologies-America (HMT-A) Biomarker discovery team since 2013, where he partners with biopharmaceutical companies to bring high resolution quantitative metabolomics profiling to pre-clinical and clinical studies. Prior to joining Human Metabolome Technologies, Dr. Búko was Senior Director Translational Medicine at Biogen for 10 years and Principal Investigator at Abbott labs for 18 years. He received his Ph.D. in Chemistry from the University of Virginia, with post-doctoral work for Bureau of Biologics and Biophysics at Food and Drug administration.

Dr. Búko’s career has focused primarily on omics solutions for biomarker and target discovery within the biopharma pipeline. Most of his work has been in immunology, infectious disease and neurology, however, at HMT-A he has widened his scope to many other therapeutic areas. While in biopharma Alex managed biomarker pipelines from pre-clinical to clinical studies using various protein and small molecule technologies to discovery and validate biomarkers for drug development and patient stratification. Dr. Búko’s areas of expertise include proteomics, lipidomics, metabolomics, protein assays and the statistical and biological pathway approaches required to combine omics data and generate prognostic and diagnostic algorithms.

Fred Baribaud holds a PhD from the University of Lausanne and has conducted postdoctoral studies at the University of Pennsylvania. He has worked at Incyte Corporation in a discovery role on target validation and as a compound team co-lead for small molecular inhibitors. For the past ten years, Fred has worked at Janssen R&D in Immunology Biomarkers on various inflammatory diseases. In his current role as Scientific Director he is focused on obtaining disease rational for targets and patient segmentation for inflammatory bowel diseases.

For the past ten years, Fred has worked at Janssen R&D in Immunology Biomarkers on various inflammatory diseases. In his current role as Scientific Director he is focused on obtaining disease rational for targets and patient segmentation for inflammatory bowel diseases.

Dr. Martin Burow is founder and owner of the DMB-Diagnostics GmbH and specialist for medical sales and marketing activities in Asia and Europe. Martin Burow has completed his PhD in Chemistry and Biochemistry at the University of Münster in 1993 and worked 3 years as a Post-doctoral fellow for the Ministry of International Trade and Industry at the National Institute of Materials and Chemical Research (NIMC) in Tsukuba, Japan. After his return to Germany, he started his career in the medical device industry and developed the Asian-Pacific markets for Brahms-Thermofisher in the field of medical diagnostics (thyroid, sepsis, prenatal and oncology). Later, he started his own company (DMB-Diagnostics GmbH) to introduce highly innovative diagnostics worldwide for better treatment standards for oncological patients.

Biochemistry, Diagnostics, Regulatory

Leveraging a proven experience, LOUIS CAZE provides cancer patients with a wide range of care services, including Counselling, Wellness, Pain Relief and Multidisciplinary Support. Louis Caze Supportive Care Center focuses on improving quality of life for Cancer patients and their families. Following a cancer diagnosis, it is normal for patients to experience burdensome physical symptoms and/or psychological distress from their disease and/or side effects of its treatment.

Optimize healing process : reduce stress and anxiety, strengthen physical condition (Dietary follow-up, sporting exercises...) Relieve suffering and improve quality of life: helping patients get relief from symptoms caused by cancer and treatment, like pain, nausea, fatigue, shortness of breath... Better inform patients and family members via a set of services that deal with emotional and social implications of cancer treatment

Zhigang Kang has completed his PhD from University of Helsinki, Finland and Post-doctoral studies from NIMH, NIH. He is a Research Scientist in Molecular Target Core, Genetics Branch, Center for Cancer Research, National Cancer Institute and an employee of Basic Science Program, Leidos Biomedical Research, Inc., Frederick. He has been working in the field of cancer biomarkers for the past 7 years. His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

David I Smith completed his Ph.D. at the age of 23 years from the University of Wisconsin in Madison and then did post-doctoral studies at the University of California in Irvine. Since 1996 he has been a Professor at the Mayo Clinic in the Department of Laboratory Medicine and Pathology. He is also the Chairman of the Technology Assessment Group for the Center for Individualized Medicine at the Mayo Clinic. His laboratory studies the common fragile sites and the role that these regions of instability play in the development of cancer. His group also studies the different ways that HPV can contribute to the development of different cancers. He has published over 200 papers in reputed journals and serves on the Editorial Board of a number of journals.

His group also studies the different ways that HPV can contribute to the development of different cancers. He has published over 200 papers in reputed journals and serves on the Editorial Board of a number of journals.

Shivendra V. Singh earned his M.Sc. and Ph.D. degrees in Biochemistry from the Banaras Hindu University (India). In 1983, Dr. Singh came to the United States to pursue post-doctoral training at the University of Texas Medical Branch, Galveston, TX and studied glutathione-linked detoxification mechanisms. In 1988, Dr. Singh was appointed to the faculty of the University of Miami, School of Medicine as an Assistant Professor in the Department of Medical Oncology. The Mercy Hospital of Pittsburgh recruited Dr. Singh in 1992 to head its Cancer Research Laboratory and direct basic cancer research program. Dr. Singh joined the University of Pittsburgh in 2000 as a Tenured Professor of Pharmacology & Chemical Biology and member of University of Pittsburgh Cancer Institute (UPCI). Dr. Singh holds a secondary appointment in the Department of Urology in School of Medicine, and is the Associate Director for Basic Research at the UPCI. Dr. Singh was honored with UPMC Endowed Chair Cancer Prevention Research in 2014. Dr. Singh is a co-author of over 240 research articles in peer-reviewed journals and 22 review articles/book chapters. Dr. Singh serves on Editorial Boards of various scientific journals, including Cancer Prevention Research, Molecular Cancer Therapeutics, Clinical Cancer Research, Molecular Pharmacology, Molecular Carcinogenesis, Carcinogenesis, and Pharmaceutical Research to name a few. Dr. Singh has served on various grant review panels.

Carcinogenesis, Cancer Therapeutics, Biomarkers

Dr Scherer obtained his PhD at the Max-Planck-Institute for Immunobiology in Germany. After a postdoctoral position at the UT Southwestern Medical Center in Dallas, USA, until 1999, he has been working on biomarker research and development projects in various positions, in the laboratory, as bioinformatician, and as project manager. Andreas worked for Novartis in Basel, CH, from 2000 until 2007, then as consultant and bioinformatician in his own company in Finland, and as Manager of the Bioinformatics Team at the Australian Genome Research Facility (AGRF) in Melbourne, AU. He is inventor and co-inventor of several biomarker-related gene patents, published a book on microarray data quality, and is involved in international research projects and consortia, such as the US FDA-guided SEQC. Besides his work in his consultancy company “Spheromics”, Andreas is Biomarker Project Director at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, Finland, and has a role as National Coordinator in Finland of the European Research Infrastructure for Translational Medicine, EATRIS, for which he also acts as Co-chair of the Biomarker technology Platform.

Biomarkers, Translational Medicine

Dimitrios H. Roukos is currently working as Founding Director, Centre for Biosystems & Synthetic Genomic Network Medicine - CBS. GenNetMed Ioannina University- Ioannina, Greece. He is also Leader at Translational Research, European Network of Excellence (EUNE) for Gastric Cancer (since 2006) and affiliated to Department of Surgery, Ioannina University Hospital , Ioannina , Greece (since 1990). Dr. D. Roukos has graduated from Athens University School of Medicine, Greece. He underwent specialist training in surgery at the J.W.Goethe-University Hospital in Frankfurt a.M., Germany where received his Doctorate (Dr.med). He moved back to Greece and since 1990 works at the Ioannina University School of Medicine.

Genetics, Pathology, Biomarkers, Systems biology & and cancer networks

Kaushala Prasad Mishra has earned B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. His areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. He has been Research Guide for Ph.D. students in many Universities of India; Successfully guided 41 Ph.D. students and presently guiding 08 students. He has published more than 280 research papers and proceeding papers in National and International Journals. He has delivered more than 300 invited talks in Symposia and Conferences. He is currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. He also served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India, Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). He served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.

Radiation Research, Biomarkers, Biophysics, Biotechnology

Dr. (Prof.) Raisuddin is an academician, academic administrator and active researcher with a track record of over 25 years. He did his doctoral thesis (Ph.D.) work at the Indian Institute of Toxicology Research, IITR (a CSIR national laboratory), Lucknow. Initially, he worked as Scientist at IITR, Lucknow and Bose Institute, Kolkata. In 1994, he joined Jamia Hamdard (Hamdard University), New Delhi as a faculty in the Department of Medical Elementology & Toxicology. He was selected as Commonwealth Fellow in 2002 and worked for about a year at the University of Plymouth, UK as Visiting Scientist in 2003. In 2004, he visited Czech Republic under India National Science Academy (INSA) programme and spent three months as Visiting Scientist at RECETOX (an EU Centre of Excellence), Brno. For two years (2006-08) he was at Hanyang University (among top 5 Korean Universities), Seoul, South Korea as Professor. He has been the Head of the Department of Medical Elementology and Toxicology for three years (March 2012 – May 2015) and is currently Head of the Centre for Translational & Clinical Research. Dr. Raisuddin has been appointed as a member of editorial board of over a dozen international journals.

Biomarkers, Cancer markers, Molecular Biomarkers

Claudio Nicolini was born in Udine, Italy. He received the doctoral degree in physics from the University of Padua, in 1967. After serving as Adjunct Professor at the University of Bari, he moved for 17 years to the United States, of which he became citizen since 1974, and was originally at Brown University, MIT, and BNL. He then moved to Temple University School of Medicine, Philadelphia, where after a period of intensive training and research in pathology he became Associate Professor of Pathology and then Professor and Chairman of the Biophysics in 1976. In 1985, he was called as “eminent scientist” to the Chair of Biophysics of the University of Genoa, in Italy until 2012, where he was successively Director of Biophysics Institute, DISTBIMO and CIRSDNNOB. From 1993 until now is Life President of the Fondazione ELBA Nicolini and of the Nanoworld Institute. On 2008 has been elected as a Foreign Member of the Russian Academy of Sciences and on 2010 Honoris Causa Professor of Biophysics and Nanobiotechnology at Moscow State University. He was Chief Editor of Cell Biophysics (USA), Science and Technology Advisor to Italian Prime Minister Craxi, Member of the National Science and Technology Council upon Parliament election, Scientific Director Industrial Consortium CIREF, Founder Technobiochip; President Polo National Bioelectronics, President Scientific Technological Park of Elba Island. He received several awards and prizes and has authored more than 480 publications in international scientific journals (SCI), 35 patents (WPI), 28 books and Series Editor in Bioelectronics (Plenum) and Nanobiotechnology (Pan Stanford). His main scientific activities concerned cancer research, biophysics and nanotechnology, pioneering world-wide chromatin structure-function, bioelectronics and nanobiotechnology.

Cancer research, Biophysics and Nanotechnology, pioneering world-wide chromatin structure-function, Bioelectronics and Nanobiotechnology.

Dr. Alain Moreau is Full Professor in the Faculty of Dentistry and the Faculty of Medicine at the Universite de Montreal. He is the Director of Research and Chief Scientific Officer of Sainte-Justine University Hospital.Dr. Moreau received his PhD in Microbiology and Immunology from the Universite de Montreal in 1993. He did a first postdoctoral training at the Protein Engineering Center of University of Liege, Belgium (1992-1993), followed by a second postdoctoral fellowship at the Shriners Hospital for Children in Montreal affiliated with McGill University (1993-1997). Dr. Moreau is an internationally recognized expert on molecular genetics of pediatric scoliosis and osteoarthritis. His discoveries led to multiple peer-reviewed papers, international conferences as guest speaker, several awards as well as 32 patents issued.

Protein engineering, Molecular genetics, Biomarkers

Chee Gee See is the Director of Personalised Medicine at Proteome Sciences, a company providing high end mass-spectrometry based biomarker discovery and clinical utility tools, uniquely positioned to engage with pharma partners in our quest for personalised medicines. CheeGee was previously the clinical Biomarker and Experimental Medicine Leader at Roche for 5 years. He was the BEML for the Phase III pivotal TOGA study where Herceptin was trialled for the new indication of gastric cancer. He was also a BEML for CVD, CNS and immunology so his range and awareness of disease areas and their clinical development challenges is both deep and broad. CheeGee also spent 11 years at GSK where he was a genetics expert covering 3 key therapeutic areas in preclinical research within Genetics Research Europe. Prior to industry, CheeGee spent 6 years in post-doctoral academia at the University of Birmingham and University College London, most notably in the Human Genome Mapping Project. CheeGee also has dual specialist expertise as a consultant in regulatory affairs and value-based drug pricing, reimbursement and market access. CheeGee looks forward to engaging with like-minded professionals during this conference.

Personalised Medicine, biomarkers, genetics

Leticia Cano identified a native citrullinated autoantigen for rheumatoid arthritis for her PhD dissertation. She did her postdoctoral training in the laboratory of Hank Fales at the National Institutes of Health, where she identified candidate biomarkers for Dermatomyositis, Juvenile Idiopathic Arthritis, and Systemic Lupus Erythematosus. As founder and president of Biomarker Profiles Corporation, she is interested in developing methods to increase the speed of biomarker discovery.

Biomarkers

Pavel Vodicka graduated at the Medical Faculty, Charles University, Prague and in 1986 obtained PhD in biochemistry. He worked as postdoctoral fellow at the Finnish Inst. Occupat. Health, Helsinki, Finland (1987-1990) and as visiting scientist at Karolinska Institute, Huddinge, Sweden (1990-1993). Since 2002 he heads the Dept. Molec. Biol. Cancer, Inst. Exper. Medicine, Acad. Sci., Prague, Czech Republic. Pavel Vodicka has published more than 130 (total IF 552.4, 2650 citations a HI 31) articles. Since 2004, his main research topics are focused on the DNA and chromosomal damage and DNA repair functional tests in humans and on transient biomarkers in the onset of gastrointestinal cancers. In 2012 he edited the Special Issue in Mutagenesis http://mutage.oxfordjournals.org/content/27/2.toc), entitled Colorectal Cancer-Current Insights into Susceptibility.

Biochemistry, Molecular biology, biomarkers, cancer biology